FDA Approves First Gene Therapy for Childhood Alzheimer's

Parents who watch their children slowly lose abilities and memories to Sanfilippo syndrome type A have finally received the news they've been desperately waiting for. The FDA approved Fayuvi on Thursday, marking the first therapy specifically designed to treat this devastating disease sometimes called childhood Alzheimer's.

Sanfilippo syndrome type A is an ultra-rare genetic disorder that robs children of their development and ultimately their lives. The disease causes a buildup of toxic material in cells, leading to severe brain damage, developmental regression, and early death.

Ultragenyx developed the new gene therapy after years of research and clinical trials. The treatment works by delivering a functional copy of the gene that patients are missing, helping their bodies break down the harmful substances that accumulate in their brains.

Before this approval, families received a diagnosis with zero treatment options. Doctors could only advise parents to take their children home, make memories, and prepare for the worst.

"It's hard to overstate what this approval would mean for everybody who is living with this really horrific disease and watching their children suffer and pass away early," said Cara O'Neill, chief science officer of the Cure Sanfilippo Foundation. She's also the mother of Eliza O'Neill, a child with the condition who received the experimental therapy years ago.

The Ripple Effect

This approval changes everything for the small but determined Sanfilippo community. Families who once faced only heartbreak now have an action plan when they receive the diagnosis.

The breakthrough also demonstrates how far gene therapy has come in treating rare diseases. What seemed impossible a decade ago is now becoming reality for families who never gave up hope.

Beyond Sanfilippo, this approval adds to growing momentum in rare disease treatment. Each success paves the way for more research funding, faster approval pathways, and renewed hope for other families fighting different ultra-rare conditions.

When families hear those devastating words "your child has Sanfilippo" today, they'll finally hear something else too: there's treatment available.